Claims for Patent: 8,383,417

Summary for Patent: 8,383,417

Title:	Assay for monitoring parathyroid hormone (PTH) variants by tandem mass spectrometry
Abstract:	Methods are described for monitoring the amounts of PTH variants in a biological sample by digesting the sample to produce surrogate peptides specific to the targeted PTH variants, and detecting and quantifying the surrogate peptides by selective reaction monitoring (SRM) mass spectrometry, using a set of precursor-to-product ion transitions optimized for sensitivity and selectivity. The PTH variants, or a portion thereof, may be concentrated in the sample by means of immunoaffinity capture or other suitable technique. The mass spectrometric method described herein enables the concurrent measurement of peptides representative of a plurality of targeted PTH variants in a single assay.
Inventor(s):	Lopez; Mary Frances (Boston, MA), Sarracino; David A. (Andover, MA), Prakash; Amol (Cambridge, MA), Nelson; Randall W. (Phoenix, AZ), Oran; Paul (Scottsdale, AZ), Krastins; Bryan E. (Somerville, MA), Rezai; Taha (Cambridge, MA)
Assignee:	Thermo Finnigan, LLC (San Jose, CA) Intrinsic Bioprobes, Inc. (Tempe, AZ)
Application Number:	12/644,284
Patent Claims:	1. A method for concurrently monitoring parathyroid hormone (PTH) variants in a biological sample, comprising steps of: preparing a sample containing PTH peptides from the biological sample, wherein the step of preparing the sample includes purifying and concentrating the PTH variants, proteolytically digesting a portion of the biological sample to produce PTH peptides, and chromatographically separating the sample; and subjecting the prepared sample to selective reaction monitoring (SRM) tandem mass spectrometry to concurrently determine the amounts of at least a first and a second PTH peptide, wherein the first PTH peptide is specific to a first PTH variant and the second peptide is specific to a second PTH variant; wherein the first PTH variant is intact PTH and the first PTH peptide is SEQ ID NO: 7 (SVSEIQLMHNLGK), and wherein the second PTH variant is a truncated form of PTH selected from a group consisting of PTH (34-84) and PTH (7-84). 2. The method of claim 1, wherein the step of subjecting the prepared sample to SRM tandem mass spectrometry includes monitoring at least two precursor-to-product ion transitions characteristic of the first PTH peptide and at least two precursor-to-product ion transitions characteristic of the second PTH peptide. 3. The method of claim 1, wherein the at least two precursor-to-product ion transitions characteristic of the first PTH peptide are m/z 486.fwdarw.636 and 486.fwdarw.684. 4. The method of claim 1, wherein the second PTH variant is PTH (7-84) and the second PTH peptide is SEQ ID NO: 3 (LMHNLGK). 5. The method of claim 4, wherein the at least two precursor-to-product ion transitions characteristic of the second PTH peptide are selected from the group consisting of m/z 407.fwdarw.317, 407.fwdarw.431, and m/z 407.fwdarw.568. 6. The method of claim 1, wherein the second PTH variant is PTH (34-84), and the second PTH peptide is SEQ ID NO: 6 (FVALGAPLAPR). 7. The method of claim 6, wherein the at least two precursor-to-product ion transitions characteristic of the second PTH peptide are selected from the group consisting of m/z 556.fwdarw.343, 556.fwdarw.456, 556.fwdarw.553, 556.fwdarw.624, m/z 556.fwdarw.681, 556.fwdarw.794 and m/z 556.fwdarw.866. 8. The method of claim 1, wherein the biological sample is one of blood serum and blood plasma. 9. The method of claim 1, wherein the step of preparing the sample includes adding at least one internal reference standard, the reference standard being an isotopically-labeled version of one of the first or second PTH peptide.

Details for Patent 8,383,417

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-03-29